Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James E Signorovitch

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Current Medical Research and Opinion|August 9, 2014
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United StatesJames E Signorovitch, Nicholas J Vogelzang, Sumanta K Pal, et al.
Expert Opinion on Pharmacotherapy|March 14, 2015
Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United StatesMichael K Wong, Eric Jonasch, Sumanta K Pal, et al.
Journal of Neurology|July 25, 2015
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosisShahamat Tauhid, Renxin Chu, Rahul Sasane, et al.
Muscle & Nerve|June 4, 2026
Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a StudyJerry R Mendell, Zarife Sahenk, Linda P Lowes, et al.
European Heart Journal|June 27, 2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT TrialGeorge V Moukarbel, James E Signorovitch, Marc A Pfeffer, et al.
Blood Neoplasia|January 19, 2026
Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sourcesChenyu Lin, Smitha Sivaraman, Gautam Sajeev, et al.
European Journal of Endocrinology|April 25, 2014
Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's diseaseSusan M Webb, John E Ware, Anna Forsythe, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Current Medical Research and Opinion|August 9, 2014
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United StatesJames E Signorovitch, Nicholas J Vogelzang, Sumanta K Pal, et al.
Expert Opinion on Pharmacotherapy|March 14, 2015
Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United StatesMichael K Wong, Eric Jonasch, Sumanta K Pal, et al.
Journal of Neurology|July 25, 2015
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosisShahamat Tauhid, Renxin Chu, Rahul Sasane, et al.
Muscle & Nerve|June 4, 2026
Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a StudyJerry R Mendell, Zarife Sahenk, Linda P Lowes, et al.
European Heart Journal|June 27, 2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT TrialGeorge V Moukarbel, James E Signorovitch, Marc A Pfeffer, et al.
Blood Neoplasia|January 19, 2026
Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sourcesChenyu Lin, Smitha Sivaraman, Gautam Sajeev, et al.
European Journal of Endocrinology|April 25, 2014
Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's diseaseSusan M Webb, John E Ware, Anna Forsythe, et al.
Pageof 5